Predict’s Mistral Breath Test Enters Occupational Medicine in Landmark Milan Study

Predict S.P.A. Class B ( (IT:PRE) ) has shared an announcement.

Predict S.p.A., an Italian med-tech specialist in diagnostic imaging, breath analysis and digital healthcare, has built a portfolio that includes its Mistral breath-analysis technology, the Aphel AI platform for robotic support, and the Optip holopresence system for remote medical consultation and training. The company leverages long-term partnerships with major Italian academic and clinical centers to advance innovative, non-invasive healthcare solutions.

The Military Hospital Center in Milan has launched Italy’s first occupational-medicine study using Predict’s Mistral Sampler to monitor automotive-sector workers’ exposure to volatile organic compounds via non-invasive breath analysis. The pilot, which also marks Mistral’s first deployment in Lombardy, aims to validate breath testing as a rapid, complementary biomonitoring tool, potentially broadening Predict’s reach into workplace health and strengthening its position in the occupational safety market.

The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.

More about Predict S.P.A. Class B

Predict S.p.A. is an Italian med-tech SME focused on in vivo diagnostics, breath analysis and digital healthcare solutions. Organized into four business units, it distributes ultrasound and radiological imaging equipment, develops the Mistral breath-analysis platform, and offers augmented reality and robotics tools for clinicians and healthcare operators. The company collaborates with leading Italian university hospitals and research institutes and operates from Bari with a secondary office in Milan.

Average Trading Volume: 25,461

Technical Sentiment Signal: Sell

Current Market Cap: €6.44M

Learn more about PRE stock on TipRanks’ Stock Analysis page.